Results:
In this cross sectional study, performed from January 2019 to December
2020, 72 Hodgkin lymphoma survivors were screened and 60 were enrolled.
Ten children were excluded as they had completed treatment beyond 5
years of enrolment and two children were excluded as they were above 18
years of age.
Patient and disease characteristics are listed in table 1. The mean age
of the study population was 11.3 years with SD of 2.77. Majority were
males. Only three (5%) patients had clinical symptoms of dyspnea on
exertion and three (5%) patients had decreased air entry on one side on
auscultation. Out of 60 patients, 57 (95%) received ABVD regimen, at
mean age of 8.6 years, median cumulative dose of bleomycin 120mg/m2
(range 30-120mg/m2). Only three patients (5%) received cyclophosphamide
in their chemotherapy regimen. Eighteen patients (30%) received
involved field radiotherapy (IFRT) along with chemotherapy at median age
of 10.75 years, 9 (15%) received IFRT to mediastinum with dose of
25-30Gy(4 patients received 25Gy and 5 patients received 30 Gy) and 15
fraction. Median time to assess pulmonary function post completion of
treatment was 2 years. Lab parameters such as hemoglobin and total
leucocyte count were normal in all patients. Only 2 patients (3.33%)
had ejection fraction of less than 60%